We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

168 hedge funds and large institutions have $3.65B invested in Apellis Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 51 increasing their positions, 60 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 14

135% more call options, than puts

Call options by funds: $16.3M | Put options by funds: $6.96M

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

98% more capital invested

Capital invested by funds: $1.85B → $3.65B (+$1.81B)

16% more funds holding

Funds holding: 145 → 168 (+23)

2.16% more ownership

Funds ownership: 82.2% → 84.36% (+2.2%)

15% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 60

Holders
168
Holders Change
+23
Holders Change %
+15.86%
% of All Funds
2.97%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
37
Increased
51
Reduced
60
Closed
14
Calls
$16.3M
Puts
$6.96M
Net Calls
+$9.36M
Net Calls Change
+$8.31M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$51.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$36.9M
3
GTC
Ghost Tree Capital
New York
+$13.7M
4
LGM
Logos Global Management
California
+$12.7M
5
Renaissance Technologies
Renaissance Technologies
New York
+$9.15M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$32.4M
2
Millennium Management
Millennium Management
New York
-$28.6M
3
CS
Candriam SCA
Luxembourg
-$25.1M
4
State Street
State Street
Massachusetts
-$18.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
101
Rafferty Asset Management
New York
$1.07M -$2.13M -50,470 -73%
MLICM
102
Metropolitan Life Insurance Company (MetLife)
New York
$981K -$50.2K -1,187 -6%
Baird Financial Group
103
Baird Financial Group
Wisconsin
$960K -$212K -5,001 -23%
ASRS
104
Arizona State Retirement System
Arizona
$941K -$75.4K -1,783 -10%
SEI Investments
105
SEI Investments
Pennsylvania
$931K +$688K +16,268 New
FAM
106
Fred Alger Management
New York
$847K +$627K +14,811 New
QSS
107
Quantitative Systematic Strategies
Florida
$810K +$280K +6,615 +88%
B
108
Bailard
California
$801K -$123K -2,900 -17%
Susquehanna International Group
109
Susquehanna International Group
Pennsylvania
$786K -$1.23M -29,103 -68%
Lazard Asset Management
110
Lazard Asset Management
New York
$754K +$558K +13,189 New
Handelsbanken Fonder
111
Handelsbanken Fonder
Sweden
$732K – – –
JAMONY
112
Jacob Asset Management of New York
California
$572K +$423K +10,000 New
JF
113
Jump Financial
Illinois
$561K +$414K +9,797 New
Public Employees Retirement Association of Colorado
114
Public Employees Retirement Association of Colorado
Colorado
$558K – – –
AB
115
Amalgamated Bank
New York
$537K +$2.16K +51 +0.5%
EGM
116
Engineers Gate Manager
New York
$531K +$393K +9,290 New
CSS
117
Cubist Systematic Strategies
Connecticut
$511K -$857K -20,266 -69%
Los Angeles Capital Management
118
Los Angeles Capital Management
California
$504K +$15.4K +365 +4%
Zurich Cantonal Bank
119
Zurich Cantonal Bank
Switzerland
$465K – – –
ACM
120
AlphaCrest Capital Management
New York
$463K +$343K +8,100 New
BNP Paribas Financial Markets
121
BNP Paribas Financial Markets
France
$462K -$257K -6,070 -43%
BC
122
Birchview Capital
Vermont
$458K – – –
Voloridge Investment Management
123
Voloridge Investment Management
Florida
$452K +$334K +7,901 New
MML Investors Services
124
MML Investors Services
Massachusetts
$434K – – –
AAMU
125
Amundi Asset Management US
Massachusetts
$418K – – –
3 4
5
6 7

APLS Hedge Fund Activity: Q4 2020 in Review

168 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2020, worth a combined $3.65B — up 98% from $1.85B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new APLS positions and 14 closed out — a net gain of 23 holders — while 51 added to existing stakes and 60 trimmed.

The largest buyer was Vanguard Group, adding an estimated $51.8M. The largest seller was Citadel Advisors, cutting an estimated $32.4M.

  • 168 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2020, up from 145 in Q3 2020.
  • Funds reported $3.65B of Apellis Pharmaceuticals stock for Q4 2020, up 98% quarter-over-quarter.
  • 37 funds opened new Apellis Pharmaceuticals positions in Q4 2020 and 14 closed out, a net change of +23 holders.
  • The largest Apellis Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $51.8M added.
  • The largest Apellis Pharmaceuticals seller in Q4 2020 was Citadel Advisors, an estimated $32.4M sold.

Based on aggregated 13F filings for Q4 2020.